NMT-A02 shows higher efficacy and lower toxicity against all 3 animal models tested (mice, hamster and dog). Excellent results were obtained in dogs clinical trial in comparison with Milteforan® (the standard oral treatment): rapid clinical recovery, reduction of parasite burden, absence of significant key biopathological markers and reduction of IFAT titers as a diagnostic method.

NMT-A02 performs better than Milteforan®, which prompted us to propose the dogs’ adoption as a follow-up of the trial. A permit was granted by the Comunidad de Madrid Government on 11-11-2016. The agreement between the adopters and UCM was to continue the follow-up of the dogs: UCM had access to the dogs (immunology, biopathology, hematology) through their veterinarians. Follow-up results are: the NMT-A02 group of dogs showed better recovery, is in good clinical conditions and no other treatment was received after the end of the trial in contrast to the Milteforan® treated group .